RENEE BENINGER: Open Payments
NPI 1457455917 · PORTLAND, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,345 in 72 payments from 24 companies in 2025. Trend: 2023 $1,384 · 2024 $1,355 · 2025 $1,345
Food & beverage: $1,345
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $318 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $153 |
| AstraZeneca Pharmaceuticals LP | 4 | $86 |
| Novo Nordisk Inc | 4 | $86 |
| Vanda Pharmaceuticals Inc. | 3 | $82 |
| E.R. Squibb & Sons, L.L.C. | 4 | $70 |
| Supernus Pharmaceuticals, Inc. | 3 | $59 |
| Abbott Laboratories | 2 | $51 |
| Astellas Pharma US Inc | 2 | $51 |
| Lilly USA, LLC | 2 | $47 |
Products named: CAPLYTA, UBRELVY, QULIPTA, VRAYLAR, FANAPT, Wegovy, Qelbree, COBENFY.
Industry payments across OR — which companies pay providers there.
